Skip to Main Content

Author Details

Yun Jee Seo
Institute for Refractory Cancer Research, Samsung Medical Center
2004
19
15
PMIDPaper TitleJournal TitlePublished Year
36915208Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.Genome Med2023
31096737Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.Cancer Res Treat2020
32070411Comprehensive pharmacogenomic characterization of gastric cancer.Genome Med2020
32120790Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening.Cancers (Basel)2020
30085274Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.Neuro Oncol2019
30262818Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.Nat Genet2018
28263318Spatiotemporal genomic architecture informs precision oncology in glioblastoma.Nat Genet2017
27102443Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.Oncotarget2016
25549722Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.Clin Cancer Res2015
26444992FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.PLoS One2015
26084335Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.Genome Biol2015
24199994High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform.Anal Chem2014
25227876High-throughput, miniaturized clonogenic analysis of a limiting dilution assay on a micropillar/microwell chip with brain tumor cells.Small2014
25084005Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.PLoS One2014
23231684Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.Br J Pharmacol2013
17942705Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis.Proc Natl Acad Sci U S A2007
15792349Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment.Mol Cell Biochem2005
16391524Bis induces growth inhibition and differentiation of HL-60 cells via up-regulation of p27.Exp Mol Med2005
15294893CA repeats in the 3'-untranslated region of bcl-2 mRNA mediate constitutive decay of bcl-2 mRNA.J Biol Chem2004
  • 1 - 19 of 19

Recommended Authors

Princess Margaret Hospital
Career Start Year 2013
Number of shared co-authors 0
University of Turin
Career Start Year 2013
Number of shared co-authors 0
Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University)
Career Start Year 2013
Number of shared co-authors 0
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 0
Research Institute for Natural Sciences, Hanyang University
Career Start Year 2007
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Jilin University
Career Start Year 2005
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 2004
Number of shared co-authors 1
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2004
Number of shared co-authors 0
Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Huaihe Hospital of Henan University
Career Start Year 2004
Number of shared co-authors 0
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
CIMA-Universidad de Navarra
Career Start Year 2001
Number of shared co-authors 1
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 0
Nencki Institute of Experimental Biology
Career Start Year 1999
Number of shared co-authors 0
Mossakowski Medical Research Institute, Polish Academy of Sciences
Career Start Year 1999
Number of shared co-authors 1
Department of Neurosurgery at the University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 7
Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Career Start Year 1997
Number of shared co-authors 0
Henan-Macquarie University Joint Centre for Biomedical Innovation, Henan University
Career Start Year 1997
Number of shared co-authors 19
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Career Start Year 1996
Number of shared co-authors 0
University of Illinois at Urbana-Champaign
Career Start Year 1996
Number of shared co-authors 2
Northwestern University Feinberg School of Medicine
Career Start Year 1996
Number of shared co-authors 3
Fukuoka University
Career Start Year 1992
Number of shared co-authors 0
University of California San Diego
Career Start Year 1992
Number of shared co-authors 0
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Career Start Year 1992
Number of shared co-authors 8
Northwestern University
Career Start Year 1992
Number of shared co-authors 2
Peking University Cancer Hospital
Career Start Year 1989
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
Heersink School of Medicine, University of Alabama at Birmingham
Career Start Year 1984
Number of shared co-authors 6

Collaborators

Samsung Medical Center, Sungkyunkwan University School
Co-authored papers 13
Gangnam Severance Hospital
Co-authored papers 9
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 8
Korea University, College of Medicine
Co-authored papers 7
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 7
Touro College of Osteopathic Medicine
Co-authored papers 7
Samsung Genome Institute, Samsung Medical Center
Co-authored papers 7
Institute for Refractory Cancer Research, Samsung Medical Center
Co-authored papers 6
Yonsei University College of Medicine, Severance Hospital
Co-authored papers 5
Cancer Stem Cell Research Center, Samsung Biomedical Research Institute
Co-authored papers 4
Feinberg School of Medicine, Northwestern University
Co-authored papers 4
Cancer Stem Cell Research Center, Samsung Biomedical Research Institute
Co-authored papers 4
Genomic Medicine Institute, Medical Research Center, Seoul National University
Co-authored papers 4
Korea University College of Medicine
Co-authored papers 4
Samsung Medical Center, Sungkyunkwan University
Co-authored papers 4
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 3
Columbia University Vagelos College of Physicians and Surgeons
Co-authored papers 3
Research Institute for Future Medicine, Samsung Medical Center
Co-authored papers 3
Busan Paik Hospital, Inje University
Co-authored papers 3
Sungkyunkwan University
Co-authored papers 3
The Hong Kong University of Science and Technology
Co-authored papers 3
College of Medicine, Seoul National University
Co-authored papers 3
Seoul National University, College of Medicine
Co-authored papers 3
Luxembourg Institute of Health
Co-authored papers 3
University of Chinese Academy of Sciences
Co-authored papers 2
Columbia University
Co-authored papers 2
Lerner Research Institute, Cleveland Clinic
Co-authored papers 2
Research Institute of Future Medicine, Samsung Medical Center
Co-authored papers 2
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 2